Biotech and Medical Venture Deals Roundup
by Adam Rubenstein
OnBioVC
Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.
MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.
ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.
ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.
Numira Biosciences (Irvine, CA) a medical device company specializing in high resolution bone imaging and virtual histology has raised a $2.5M Series A round. The deal was led by vSpring Capital and joined by Tech Coast Angels and Pasadena Angels.
Regado Biosciences (Durham, NC) a biopharmaceutical company with a platform oligonucleotide drug-antidote pairing system focused upon the anticoagulant market has closed a $23M Series C financing. The deal was led by Caxton Advantage Life Sciences, Domain Associates, Quaker BioVentures and Aurora Funds.
Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.
CoreValve (Irvine, CA) is a medical device company introducing a percutaneous revalving system to replace failing aortic heart valves without surgical access closed a $33M Series C financing. The deal was led by Maverick Capital other participants included Apax Partners, HealthCap and Sofinnova Partners.
Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.
Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.
Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.
Coapt Systems (Palo Alto, CA) develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures raised $22.6M in a Series E financing. The deal was led by Global Life Science Ventures and Easton Capital other participants included Alta Partners, Asset Management Company, Canaan Partners, Millennia Partners and Foundation Medical Partners.
Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.
Source: OnBioVC.com
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 31, 2007
- March 24, 2007
____________________
OnBioVC
Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.
MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.
ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.
ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.
Numira Biosciences (Irvine, CA) a medical device company specializing in high resolution bone imaging and virtual histology has raised a $2.5M Series A round. The deal was led by vSpring Capital and joined by Tech Coast Angels and Pasadena Angels.
Regado Biosciences (Durham, NC) a biopharmaceutical company with a platform oligonucleotide drug-antidote pairing system focused upon the anticoagulant market has closed a $23M Series C financing. The deal was led by Caxton Advantage Life Sciences, Domain Associates, Quaker BioVentures and Aurora Funds.
Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.
CoreValve (Irvine, CA) is a medical device company introducing a percutaneous revalving system to replace failing aortic heart valves without surgical access closed a $33M Series C financing. The deal was led by Maverick Capital other participants included Apax Partners, HealthCap and Sofinnova Partners.
Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.
Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.
Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.
Coapt Systems (Palo Alto, CA) develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures raised $22.6M in a Series E financing. The deal was led by Global Life Science Ventures and Easton Capital other participants included Alta Partners, Asset Management Company, Canaan Partners, Millennia Partners and Foundation Medical Partners.
Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.
Source: OnBioVC.com
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 31, 2007
- March 24, 2007
____________________
posted by Nico at
3:41 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home